Alterity Therapeutics (NASDAQ:ATHE) Rating Increased to Hold at Zacks Research

Alterity Therapeutics (NASDAQ:ATHE) was upgraded by equities research analysts at Zacks Research to a “hold” rating in a note issued to investors on Wednesday,Zacks.com reports.

Several other research firms also recently weighed in on ATHE. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alterity Therapeutics in a research report on Monday, April 20th. LADENBURG THALM/SH SH began coverage on shares of Alterity Therapeutics in a research report on Tuesday. They set a “buy” rating and a $10.00 price objective for the company. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Alterity Therapeutics has an average rating of “Hold” and an average target price of $10.00.

Alterity Therapeutics Price Performance

ATHE opened at $4.88 on Wednesday. The company’s 50 day moving average is $4.31 and its 200 day moving average is $3.69. Alterity Therapeutics has a 12-month low of $4.14 and a 12-month high of $350.00.

Institutional Trading of Alterity Therapeutics

An institutional investor recently bought a new stake in Alterity Therapeutics stock. Citadel Advisors LLC purchased a new position in Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 22,144 shares of the company’s stock, valued at approximately $83,000. Citadel Advisors LLC owned approximately 0.25% of Alterity Therapeutics at the end of the most recent quarter. Institutional investors own 2.14% of the company’s stock.

Alterity Therapeutics Company Profile

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.